SATURN is a multicenter, pragmatic, prospective, randomized, open-label, and blinded end-point assessment (PROBE) clinical trial in patients with spontaneous lobar ICH who are taking a statin drug at the time of ICH onset. A total of 1,456 patients will be recruited at up to 140 sites in the USA and Canada. Subjects will be followed for up to 24 months for the primary efficacy outcome of the effects of continuation vs. discontinuation of statins on the risk of ICH recurrence during 24 months of follow-up in patients presenting with a spontaneous lobar lCH while taking a statin drug.